Core Viewpoint - The AH innovative drug concept is experiencing a rebound, with significant trading activity in the Hong Kong and A-share markets, indicating strong investor confidence in the sector [1][8]. Group 1: Market Performance - The Hong Kong innovative drug ETF (520880) saw a strong afternoon recovery after an initial dip, maintaining a wide premium and achieving nearly 700 million HKD in trading volume [1][8]. - Over the previous four trading days, the Hong Kong innovative drug ETF (520880) recorded a net subscription of 96.3 million HKD, reflecting positive market sentiment [1][8]. - As of September 3, the year-to-date cumulative increase of the Hong Kong innovative drug ETF (520880) reached 118.95%, leading among similar indices [11][12]. Group 2: Stock Performance - The performance of individual stocks within the Hong Kong innovative drug ETF (520880) was mixed, with notable gains from Yaojie Ankang-B (up 17%) and Ying'en Biotechnology-B (up over 10%), while Kangfang Biotechnology and Lepu Biopharma saw declines of nearly 7% and over 4%, respectively [3][10]. - The newly included stocks in the ETF are all focused on innovative drug research and development, including major players like Hengrui Medicine (market cap of 572.13 billion HKD) and other emerging companies [3][11]. Group 3: Index Adjustments - The index tracked by the Hong Kong innovative drug ETF (520880) underwent a "purification" process effective September 8, removing companies involved in CXO services and increasing the total number of constituent stocks to 37 [3][10]. - The adjustment aims to enhance the index's focus on pure innovative drug companies, potentially increasing its performance during the upward cycle of the innovative drug industry [11].
“提纯”生效首日，港股通创新药ETF（520880）溢价高企！新进成份股药捷安康-B飙升17%